|Bid||63.03 x 900|
|Ask||63.18 x 800|
|Day's Range||61.80 - 63.21|
|52 Week Range||57.19 - 74.12|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||17.65|
|Earnings Date||Jul 27, 2022 - Aug 01, 2022|
|Forward Dividend & Yield||2.92 (4.69%)|
|Ex-Dividend Date||Jun 14, 2022|
|1y Target Est||69.52|
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
FOSTER CITY, Calif., May 16, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP). As previously announced, the FDA had placed a clinical hold on the use of injectable lenacapavir in borosilicate vials due to a vial compatibility issue. FDA removed the clinical
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...